Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Malignant Melanoma
Interventions
DRUG

HSPPC-96 or Oncophage

Trial Locations (77)

Unknown

Birmingham

Scottsdale

Berkeley

Los Angeles

Stanford

Vista

Denver

Farmington

Jacksonville

Lakeland

Miami Beach

Atlanta

Chicago

Park Ridge

Kansas City

Louisville

Baltimore

Boston

Robbinsdale

Rochester

Columbia

St Louis

Lebanon

New Brunswick

New York

Cincinnati

Cleveland

Tulsa

Portland

Philadelphia

Pittsburgh

Knoxville

Dallas

Houston

Madison

Adelaide

Camperdown

Melbourne

Newcastle

Wentworthville

Budapest

Debrecen

Pécs

Szeged

Aviano

Genova

Milan

Rimini

Bialystock

Bydgoszcz

Krakow

Arkhangelsk

Chelyabinsk

Kazan'

Krasnodar

Moscow

Novosibirsk

Ryazan

Saint Petersburg

Samara

Stavropol

Voronezh

Gothenburg

Lund

Vaxjo

Dnipro

Donetsk

Ivano-Frankivsk

Kiev

Kryvyi Rih

Lviv

Odesa

Uzhhorod

Vinnitsa

Leeds

London

Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Agenus Inc.

INDUSTRY